Cargando…

Omalizumab for urticaria treatment in clinical practice: a case series

INTRODUCTION: Omalizumab (Xolair) originally intended to reduce symptoms of moderate to severe asthma uncontrollable with steroids is the first monoclonal antibody approved for treatment of chronic spontaneous urticaria in 2014. AIM: To evaluate response and potential side effects to omalizumab trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lesiak, Aleksandra, Bednarski, Igor A., Maćkowska, Anna, Łukasik, Zuzanna, Woźniacka, Anna, Olejniczak-Staruch, Irmina, Narbutt, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130138/ https://www.ncbi.nlm.nih.gov/pubmed/30206449 http://dx.doi.org/10.5114/ada.2018.77666

Ejemplares similares

Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects
por: Lesiak, Aleksandra, et al.
Publicado: (2019)

Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis
por: Olejniczak-Staruch, Irmina, et al.
Publicado: (2020)

AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings
por: Olejniczak-Staruch, Irmina, et al.
Publicado: (2021)

Can biologic treatment induce cutaneous focal mucinosis?
por: Lesiak, Aleksandra, et al.
Publicado: (2014)

Ultraviolet Radiation and Chronic Inflammation—Molecules and Mechanisms Involved in Skin Carcinogenesis: A Narrative Review
por: Ciążyńska, Magdalena, et al.
Publicado: (2021)

Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis
por: Olejniczak-Staruch, Irmina, et al.
Publicado: (2021)

The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review
por: Ciążyńska, Magdalena, et al.
Publicado: (2021)

Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis?
por: Lesiak, Aleksandra, et al.
Publicado: (2016)

TaaI/Cdx-2 AA Variant of VDR Defines the Response to Phototherapy amongst Patients with Psoriasis
por: Lesiak, Aleksandra, et al.
Publicado: (2021)

One week of exposure to sunlight induces progerin expression in human skin
por: Lesiak, Aleksandra, et al.
Publicado: (2017)

Prospective 3-month study on the efficacy of UV-free blue light in mild psoriasis vulgaris treatment
por: Lesiak, Aleksandra, et al.
Publicado: (2021)

Trends in basal cell carcinoma incidence rates: a 16-year retrospective study of a population in central Poland
por: Ciążyńska, Magdalena, et al.
Publicado: (2018)

The effect of an emollient with benfothiamine and Biolin prebiotic on the improvement of epidermal skin function
por: Narbutt, Joanna, et al.
Publicado: (2016)

Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients
por: Narbutt, Joanna, et al.
Publicado: (2012)

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
por: Ivyanskiy, Ilya, et al.
Publicado: (2012)

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
por: Lefévre, Anna Cecilie, et al.
Publicado: (2013)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Incapacitating solar urticaria: successful treatment with omalizumab
por: Kieselova, Katarina, et al.
Publicado: (2019)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Serum Biomarkers of Inflammation and Turnover of Joint Cartilage Can Help Differentiate Psoriatic Arthritis (PsA) Patients from Osteoarthritis (OA) Patients
por: Waszczykowski, Michał, et al.
Publicado: (2020)

The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
por: Waszczykowski, Michał, et al.
Publicado: (2020)

NLRP1 and NLRP3 inflammasomes as a new approach to skin carcinogenesis
por: Ciążyńska, Magdalena, et al.
Publicado: (2020)

Atopic dermatitis patients carrying G allele in –1082 G/A IL-10 polymorphism are predisposed to higher serum concentration of IL-10
por: Lesiak, Aleksandra, et al.
Publicado: (2014)

T cell activity in successful treatment of chronic urticaria with omalizumab
por: Sánchez-Machín, Inmaculada, et al.
Publicado: (2011)

Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
por: Nam, Young-Hee, et al.
Publicado: (2012)

269 Refractory Chronic Urticaria Treated with Omalizumab
por: Saenz, Martinez, et al.
Publicado: (2012)

Efficacy and safety of omalizumab therapy in urticaria vasculitis
por: Petrelli, Fiorella, et al.
Publicado: (2022)

Serum concentration of matrix metalloproteinases and angiogenic factors in patients with venous leg ulcers
por: Kolano, Paweł, et al.
Publicado: (2021)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
por: Galica, Katarzyna, et al.
Publicado: (2020)

Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage
por: Waszczykowski, Michał, et al.
Publicado: (2020)

Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice
por: Vollono, Laura, et al.
Publicado: (2019)

Repeated Doses of UVR Cause Minor Alteration in Cytokine Serum Levels in Humans
por: Narbutt, Joanna, et al.
Publicado: (2005)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports
por: Brodská, Petra, et al.
Publicado: (2012)

281 Use of Monoclonal Antibody Omalizumab in the Treatment of Urticaria Chronic
por: Correa, Jorge Vargas
Publicado: (2012)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Long term treatment with omalizumab in adolescent with refractory solar urticaria
por: Iannelli, Mauro, et al.
Publicado: (2021)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7svg911i63rbdcrjimhqir9ivr